Neuramis and Saypha Fillers in Korea: How HA Filler Brands Differ

Neuramis and Saypha are two hyaluronic acid dermal filler families widely used in Korean clinics, and the main difference between them is origin and design philosophy: Neuramis is made in Korea by Medytox, while Saypha is manufactured in Austria by Croma-Pharma.

Patients often arrive at a Korean consultation expecting the filler decision to be about one product being stronger or longer-lasting than another. In practice the decision is about gel properties matched to a specific anatomical job. A gel suited to lifting a flat midface behaves badly in a lip, and a gel designed for fine lines cannot project a chin. This guide explains what actually differs between these two families, how to read the product tiers within each, and what to ask so that the brand conversation becomes a useful one rather than a sales one.

What hyaluronic acid fillers are and why brands differ at all

Hyaluronic acid is a sugar molecule naturally present in skin, where it binds water. Injectable fillers use a laboratory-produced version that has been cross-linked so it resists breakdown and holds its shape. Nearly all modern HA fillers are cross-linked with the same agent, BDDE. The differences between brands come from how much HA is in the gel, how heavily and how uniformly it is cross-linked, whether the gel is monophasic or biphasic, and the particle size. Those variables determine two properties that matter clinically: how firmly the gel resists deformation, and how readily it integrates into soft tissue.

Neuramis: the Korean-made family

Neuramis is produced by Medytox, the same company behind several Korean botulinum toxin products. It is a monophasic, cross-linked HA filler supplied in a range of tiers, and lidocaine-containing versions are available in most tiers to reduce injection discomfort.

How the Neuramis tiers are intended to be used

The lighter members of the range are formulated for superficial placement, including fine lines and skin-quality work. The mid-range is designed for the dermal and deep dermal correction of folds such as the nasolabial fold. The firmer, higher-projection members are intended for deep placement on or near bone for volumising and contouring work, such as cheek or chin augmentation. Medytox has also obtained European certification under the EU Medical Device Regulation for products in the range, which is a meaningful marker because MDR conformity assessment is more demanding than the regime it replaced. That is a regulatory fact about the product, not a clinical claim that it performs better.

Saypha: the imported Austrian family

Saypha is Croma-Pharma's HA filler line, manufactured in Austria and formerly marketed under a different brand name in several markets. It is monophasic and cross-linked, and it is distributed in Korea alongside domestic products. The range spans a skin-quality product designed for fine hydration and biostimulation-style treatment, mid-range gels for folds, and firmer volumising gels for deeper structural work.

For a patient the practical significance of the import is availability and price rather than performance. Imported products generally carry higher acquisition costs for the clinic, which is usually reflected in the quoted price per syringe. That does not make them better. It makes them differently positioned in a clinic's price list.

Neuramis versus Saypha: what actually distinguishes them

Both are monophasic BDDE-cross-linked HA gels with tiered ranges covering broadly the same clinical territory, and both are used routinely and competently in Korean practice. Independent head-to-head trials comparing these two specific families against one another are limited, so any confident claim that one outperforms the other should be treated with caution.

The honest summary is that the differences that matter to your result are smaller than the differences between two injectors, and smaller than the difference between choosing the right tier and the wrong one. Where the choice does carry weight is in continuity: if you intend to maintain treatment over years, using a product that is available in your own country makes touch-ups and revision simpler. Saypha, as a European-manufactured line, is distributed more widely in Europe; Neuramis has broader availability across Asian markets. Choosing for continuity is a more rational basis than choosing for a claimed performance edge.

Duration: what to expect and what not to believe

Published data across HA fillers generally supports a duration in the region of six to twelve months for mid-range gels in mobile areas such as the lips and nasolabial folds, and longer, often twelve to eighteen months or more, for firm gels placed deep on bone in low-movement areas. Individual variation is substantial and is driven by placement depth, the volume used, the mobility of the treated area, and individual metabolism.

Claims of a fixed duration for a named product should be read as averages at best. If a clinic quotes you a single number of months as a guarantee, that is a marketing statement. Ask instead what the clinic's own review interval is, and what the policy is if correction settles faster than expected.

Safety considerations that apply to both

The risks of HA filler are properties of the procedure and the anatomy, not of the brand. The most serious is inadvertent intravascular injection, which can cause vascular occlusion and, rarely, skin necrosis or visual loss. Risk is concentrated in high-danger zones including the glabella, the nose and the tear trough. Reducing that risk depends on an injector who understands facial vascular anatomy, uses appropriate technique, and has hyaluronidase immediately available to dissolve HA in an emergency.

Before any filler treatment, confirm that hyaluronidase is stocked on site and that the clinician has a written protocol for suspected vascular compromise. Also disclose any history of autoimmune disease, recent dental work, planned vaccination or previous filler in the same area, since all of these influence planning. Delayed inflammatory nodules are an uncommon but recognised complication of HA fillers generally and are described in the peer-reviewed literature; they are treatable but require access to a clinician who recognises them.

How to make the brand conversation useful

Describe the outcome you want in anatomical terms rather than naming products. Saying that you want more projection at the chin, or softening of a fold that is visible at rest, gives the clinician something to plan against. Then ask which gel tier they propose and why that firmness suits that layer, how many millilitres they expect to use, and what the total cost is for the full plan rather than per syringe.

Ask to see the syringe and its labelling before injection. Ask whether the product holds current Korean approval. Ask what the review schedule is and whether a top-up within a defined window is included. Finally, request a written record of product name, lot number, volume and injection sites before you leave the clinic, which is the single most useful document you can carry home.

Frequently asked questions

Is a Korean-made filler lower quality than a European one?

No. Manufacturing origin does not determine quality. Both families are produced under regulated quality systems and both hold relevant approvals. Price differences largely reflect import costs and market positioning rather than a quality gap.

Can these two products be mixed in the same treatment session?

Using different gel tiers in different areas during one session is routine practice, and the tiers may come from different brands. What matters is that each gel is matched to the layer and the job. Ask your clinician to explain the plan area by area.

Can either be dissolved if I dislike the result?

Yes. Both are hyaluronic acid, so both can be broken down with hyaluronidase. Dissolving is not always perfectly predictable and may need more than one session, so it should be treated as a remedy rather than a reason to be casual about the initial decision.

Which lasts longer?

There is no reliable basis for ranking these two families against each other on duration. Within either family, the firmer gels placed deep in low-movement areas last longer than lighter gels placed superficially in mobile areas. Tier and placement matter more than brand.

Should I choose the brand available in my home country?

If you plan long-term maintenance, there is a practical argument for it, because continuity simplifies later top-ups and any revision. It is a reasonable tie-breaker when the clinical recommendation is otherwise equivalent.

Where to go from here

Choose the injector before the product. Confirm that hyaluronidase is on site, that you understand which tier is going where and why, and that you will leave with a written record including lot numbers. If you are travelling for treatment, ask how the clinic handles review and correction once you have flown home, because that answer will shape your experience more than the name on the syringe. Our guides on vetting a Korean clinic and on how hyaluronidase works cover the next steps in detail.

Sources and further reading: Ministry of Food and Drug Safety (Korea) medical device licensing information; European Medical Device Regulation conformity information; Korean Society of Plastic and Reconstructive Surgeons; peer-reviewed filler safety and complication literature indexed in PubMed. This article is general information and does not replace individual medical assessment.